TEL AVIV, Israel, April 16, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the first quarter ended March 31, 2015, before the market open, and will host a corporate update conference call and webcast on Wednesday, May 6 at 8:30 am Eastern Time.
| Conference Call & Webcast | |
| Wednesday, May 6 @ 8:30 am Eastern Time/5:30 am Pacific Time | |
| Domestic: | 855-469-0611 |
| International: | 484-756-4341 |
| Passcode: | 29527840 |
| Webcast: | http://www.alcobra-pharma.com/events.cfm |
| Replays available through May 20, 2015 | |
| Domestic: | 855-859-2056 |
| International: | 404-537-3406 |
| Passcode: | 29527840 |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and Fragile X Syndrome. MDX has completed multiple Phase II studies in adults and adolescents with ADHD and has completed a Phase III study in adults with ADHD. The company is conducting a Phase II trial in adolescents and adults with Fragile X Syndrome. For more information please visit the Company’s website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661
Help employers find you! Check out all the jobs and post your resume.
